70亿!30岁“富四代”收购上海创新药企

36氪
18 Jul

文|胡香赟编辑|海若镜“直到上周五开董事会时,礼新医药BD的两款药物都在正常推进研发,跨国药企很重视。”7月17日的并购说明会上,中国生物制药(01177.HK,下称“中生制药”)董事会主席谢其润回应了市场对礼新医药的产品可能被退货的传闻。就在3天前,中生制药宣布,以9.5亿美元对价(约合68亿人民币)100%收购本土创新药公司礼新医药。收购完成后,礼新医药团队将集体加入中国生物制药,并“给予相应...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10